Related Experiment Videos
Fetal malformation due to phenobarbitone. A case report
Insights
Exposure to phenobarbitone during pregnancy can cause birth defects, including facial and digital anomalies and developmental delays. This case highlights the teratogenic risks of anticonvulsants and suggests safer treatment guidelines for pregnant individuals.
Area of Science:
- Medical Genetics
- Pharmacology
- Teratology
Background:
- Anticonvulsant medications are frequently prescribed for epilepsy and other conditions.
- Phenobarbitone is a commonly used, long-standing anticonvulsant.
- The potential for drug-induced developmental abnormalities during gestation is a significant concern in prenatal care.
Observation:
- A case report details a child born with distinct facial and digital anomalies.
- The child also presented with significant mental retardation.
- Prenatal exposure to phenobarbitone was identified as a potential causative factor.
Findings:
- Phenobarbitone exposure during gestation is associated with teratogenic effects.
- The observed anomalies in the child are consistent with known risks of certain anticonvulsants.
- This case underscores the importance of evaluating the safety profile of medications during pregnancy.
Implications:
- There is a need for cautious prescribing of phenobarbitone and similar anticonvulsants in pregnant individuals.
- Development of evidence-based guidelines for anticonvulsant therapy during pregnancy is crucial.
- Further research into safer alternatives and risk mitigation strategies for teratogenic medications is warranted.
Abstract:
A child with facial and digital anomalies and mental retardation after exposure to phenobarbitone during gestation is presented. The teratogenicity of anticonvulsants, including phenobarbitone, is discussed, and guidelines for anticonvulsant therapy during pregnancy are suggested.